Search Results
Your search for ,WHo matches 20407 pages
Showing 1951 - 2000Recent FDA Approvals in Breast Cancer
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and expanded indications for older therapeutic agents used in breast cancer. Abemaciclib Plus Endocrine Therapy On March 3, 2023, the FDA expanded the indication for abemaciclib with endocrine...
Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD
The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...
Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer
Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...
Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?
Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...
Expert Point of View: Polly Niravath, MD and Virginia Kaklamani, MD
The invited discussant of the SOFT analysis was Polly Niravath, MD, Associate Professor and Director of the Cancer Survivorship Program at Houston Methodist Hospital in Texas. She noted that the study evaluated the use of the Breast Cancer Index (BCI) as a prognostic tool in early hormone...
SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression
In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...
Expert Point of View: Virginia Kaklamani, MD
Virginia Kaklamani, MD, Professor of Medicine at the University of Texas (UT) Health Science Center San Antonio and leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, was enthusiastic about the results of the phase III CAPItello-291 trial. “The phase III...
Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
The combination of capivasertib, an AKT pathway inhibitor, plus fulvestrant, an estrogen receptor antagonist, significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results of...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine and Chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, said that the study points the way to further exploration of the benefit of adding immunotherapy to treatment after patients develop resistance to CDK4/6 inhibitors for ...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
Expert Point of View: Seth Wander, MD, PhD
Seth Wander, MD, PhD, Assistant Professor, Mass General Cancer Center, Boston, commented on the findings of the EMERALD trial. “We have seen a large amount of new data emerging related to elacestrant and other novel SERDs [selective estrogen receptor degraders]. Despite initial expectations based...
EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer in the ...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
Expert Point of View: Ines Vaz-Luis, MD, PhD
The invited discussant of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, Ines Vaz-Luis, MD, PhD, of the Breast Cancer Survivorship Group, Gustave Roussy, Villejuif, France, pointed out that the benefit of ovarian suppression or ablation in reducing breast cancer...
EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
Many Survivors of Childhood Cancer Experience Lifelong Chronic Health Problems and Shorter Lifespans Than Their Healthier Peers
Each year, nearly 16,000 children between the ages of 0 and 19 years are diagnosed with cancer, and more than 85% survive for at least 5 years. Overall, this is a large increase in survivors since the mid-1970s, when the 5-year survival rate was just 58%. Today, approximately 500,000 people in the...
Rates of VTE Chemoprophylaxis Prescriptions and VTE Diagnosis After Major Cancer Surgery
In a retrospective cohort study reported in JAMA Network Open, Logan et al found that inpatient venous thromboembolism (VTE) chemoprophylaxis prescription rates were high and postsurgical VTE rates were low among U.S. veterans undergoing major cancer surgery. Study Details The study included 30,039 ...
Tumor Debulking Plus Palliative Chemotherapy May Not Impact Quality of Life in Patients With Metastatic Colorectal Cancer
Intensive local-regional tumor debulking in addition to standard palliative chemotherapy may not impact the overall quality of life of patients with metastatic colorectal cancer, according to a novel study published by Bakkerus et al in JNCCN–Journal of the National Comprehensive Cancer Network....
FDA Approves Adjuvant Nivolumab for Stage IIB/IIC Melanoma
On October 13, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage IIB or IIC melanoma in patients aged 12 years and older. CheckMate 76K Efficacy was evaluated in CheckMate 76K (ClinicalTrials.gov identifier NCT04099251),...
Lung ART Trial: End of the Road for Postoperative Radiotherapy?
Lung cancer is a significant global health issue, remaining the leading cause of cancer-related deaths with 2.1 million new cases and 1.8 million deaths. Complete surgical resection is the treatment of choice for operable early-stage non–small cell lung cancer (NSCLC) and resectable stage IIIA...
Can AI Help Identify Kidney Tumors That May Respond to Immunotherapy?
Clear cell renal cell carcinoma is the most common type of kidney cancer, comprising 80% of all malignant tumors found within the kidney. Although some clear cell renal cell carcinoma tumors are sensitive to immune checkpoint inhibitors, currently, there are no measures to predict whether a tumor...
How War Has Disrupted the Management of Patients With Breast Cancer in Sudan
Sudan is the third-largest country in Africa, spanning 1,886,068 km2. It is situated in an area surrounded by North Africa, Sub-Saharan Africa, and the Middle East. As of 2020, Sudan had a population of approximately 43.8 million people, with a significant proportion being younger than age 15....
Expert Point of View: Michail Ignatiadis, MD, PhD and Stephen R.D. Johnston, MD, PhD
The September 2023 European Society for Medical Oncology (ESMO) Virtual Plenary presentation of the NATALEE health-related quality-of-life (QOL) findings was discussed by Michail Ignatiadis, MD, PhD, and Stephen R.D. Johnston, MD, PhD. Dr. Ignatiadis is Director of the Breast Medical Oncology...
Prophylactic Salpingo-Oophorectomy and Survival After Resection of Germline BRCA1/2-Mutant Breast Cancer
In an Italian single-institution retrospective study reported in JAMA Surgery, Martelli et al found that prophylactic salpingo-oophorectomy was associated with improved overall survival in patients who had undergone resection of germline BRCA1/2-mutant breast cancer. Study Details The study...
Rectal Cancer Managed by Watch-and-Wait Strategy: Validation of Immunoscore Biopsy
In an international validation study reported in the Journal of Clinical Oncology, El Sissy et al found that the Immunoscore biopsy was capable of distinguishing risk of disease recurrence in patients with rectal cancer treated with a watch-and-wait strategy. As stated by the investigators, “No...
Chemical Hair Relaxers May Increase Risk of Uterine Cancer Among Black Women
Researchers have found that long-term use of chemical hair relaxers may be associated with an increased risk of uterine cancer in postmenopausal Black women, according to a recent study published by Bertrand et al in Environmental Research. Background Chemical hair relaxers are heavily marketed to...
Nonmelanoma Skin Cancers May Have Higher Mortality Rate Than Melanoma
Nonmelanoma skin cancer may be causing a greater number of global deaths than melanoma, according to findings presented by Salah et al at the European Academy of Dermatology and Venerology Congress 2023. Investigators also suggested that nonmelanoma skin cancer may be underreported and that the...
Germline Variants and Risk of Aggressive Prostate Cancer
In a study reported in JAMA Oncology, Darst et al identified germline genetic variants that were associated with increased risk of aggressive vs nonaggressive prostate cancer. As stated by the investigators, “Germline gene panel testing is recommended for men with advanced prostate cancer or a...
Cadonilimab, an Anti–PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors
In a Chinese phase 1b/II trial (COMPASSION-03) reported in The Lancet Oncology, Gao et al found that the anti–PD-1/CTLA-4 bispecific antibody cadonilimab showed activity in previously treated patients with a range of advanced solid tumors, including advanced cervical cancer, esophageal squamous...
FDA Grants Marketing Authorization to Edison Histotripsy System for Treatment of Liver Tumors
On October 9, HistoSonics, the manufacturer of the Edison System and novel histotripsy therapy platforms, announced the marketing authorization of its platform via the U.S. Food and Drug Administration's (FDA) De Novo Classification Request process, a rigorous premarket review pathway for medical...
Adjuvant Canakinumab in Completely Resected NSCLC
In the phase III CANOPY-A trial reported in Journal of Clinical Oncology, Edward B. Garon, MD, and colleagues found that adjuvant therapy with the interleukin (IL)-1β pathway inhibitor canakinumab did not significantly improve disease-free survival vs placebo in patients with completely resected...
Investigators Compare Health Information Exchange Data With Patient Self-Reported Data to Measure Cancer Screening Uptake
Investigators have determined that knowing which patient populations are following cancer screening guidelines may be beneficial to public health officials, policymakers, and researchers developing strategies to improve screening adherence, according to a recent study published by Bhattacharyya et...
Children of Young Female Patients With a History of Cancer May Be at Risk of Birth Defects
The children of adolescent and young adult female patients with a history of cancer may face a higher risk of birth defects, according to a recent study published by Murphy et al in Cancer Epidemiology, Biomarkers & Prevention. Background “Concerns like the health of future children are at the ...
Guideline Update Reflects Recent Surge of New Data in Systemic Therapy for Melanoma
A guideline update on systemic treatment for melanoma offers new guidance in several areas, including the selection of front-line therapy for patients with metastatic disease with and without BRAF mutations, treatment of patients with earlier-stage disease in the adjuvant setting, and emerging...
Accelerated Approval Granted for Use of Elranatamab-bcmm in Relapsed or Refractory Multiple Myeloma
On August 14, 2023, the bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager elranatamab-bcmm was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...
Expert Point of View: Gentry King, MD
Gentry King, MD, Assistant Professor in the Division of Hematology and Oncology, University of Washington, and Assistant Professor in the Clinical Research Division of Fred Hutchinson Cancer Center, Seattle, offered his thoughts on the findings of NuTide:121. “Only recently, with TOPAZ-1...
NUC-1031/Cisplatin Fails to Improve Outcomes in Advanced Biliary Tract Cancer
As a first-line treatment for advanced biliary tract cancer, an experimental formulation of gemcitabine, NUC-1031, given with cisplatin failed to improve outcomes over standard gemcitabine/cisplatin in the global phase III NuTide:121 trial.1 “NuTide:121 has not advanced the field in biliary tract...
Expert Point of View: Justin F. Gainor, MD
Justin F. Gainor, MD, Director of the Center for Thoracic Cancers Program at Massachusetts General Hospital, Boston, was invited to discuss IMpower151 and ILLUMINATE at the 2023 World Conference on Lung Cancer. IMpower151 vs IMpower150 Dr. Gainor examined why IMpower151 was negative for both...
Checkpoint Inhibitors Offer Limited Benefit in EGFR-Mutated Lung Cancer After Disease Progression
In advanced non–small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR), the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study ...
Tracking the Progress Being Made in the Treatment of Breast Cancer and the Challenges Ahead
Jame Abraham, MD, FACP, has been in the field of oncology for more than 2 decades, he and says this is both one of the most exhilarating and challenging times in cancer care. “What excites me the most are the innovations in treatment that are literally transforming the lives of our patients and...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
Do Patients With Advanced Cancer Value Quality Over Quantity of Life?
A recent study published by Yong et al in Value in Health may help clarify the intricate interplay between the quality-of-life and survival preferences of patients with advanced cancer. Limited access to palliative care services may contribute to suffering, particularly among patients with cancer...
KRAS G12C Inhibitors: Durability of Response, Efficacy in Combination, in NSCLC
At the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, the benefit of two KRAS G12C inhibitors in advanced non–small cell lung cancer (NSCLC) was upheld by the 2-year follow-up analysis of adagrasib in the KRYSTAL-11 and the early-phase CodeBreaK 101...
Dendritic Cell Vaccine Plus Stem Cell Transplant for Multiple Myeloma
Although the development of new therapies for multiple myeloma has significantly improved response rates and outcomes for patients with the blood cancer, most patients eventually relapse, including those who initially achieved remission. A phase I study is investigating whether a dendritic cell...
Chemotherapy Shortages Ongoing, According to New Survey
The National Comprehensive Cancer Network® (NCCN®) has released a follow-up survey on the ongoing chemotherapy shortages, refreshing findings they originally shared in June 2023. According to their results, 72% of the cancer centers surveyed continue to experience a shortage of carboplatin, and 59% ...
Neighborhood Walkability and Risk of Obesity-Related Cancers
Residing in more walkable neighborhoods could protect against the risk of overall obesity-related cancers in female patients, according to a recent study published by India-Aldana et al in Environmental Health Perspectives. Background Obesity has previously been linked to an increased risk of...
A Diagnosis of Ewing Sarcoma Altered the Trajectory of My Life
In August 2014, just a few weeks after my 15th birthday, my body began sending me a lot of worrisome signals that life as I knew it would soon be over. The year before, I had developed a hematoma in my right femur, which was resolved with surgery. But now the pain I was experiencing in that leg was ...
From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...
National Inventors Hall of Fame Recognizes Jennifer Doudna, PhD; Emmanuelle Charpentier, PhD; and Angela Hartley Brodie, PhD
The National Inventors Hall of Fame (NIHF) recognizes the enduring legacies of exceptional U.S. patent holders on an annual basis. On October 26, 2023, three female inductees will be recognized for their extraordinary contributions to cancer care and clinical research. Biochemist Jennifer...
